KSQ Therapeutics announces FDA clearance of IND for KSQ-001EX
Human Gene Editing
Nov 29, 2023
Last week:
Management news
CRISPR Therapeutics lays off 10% of employees due to market challenges
Human Gene Editing
Nov 22, 2023
M&A
Homology Medicines merges with Q32 Bio to advance clinical development
Human Gene Editing
Nov 16, 2023
Industry news
Vertex-CRISPR’s gene editing drug Casgevy gets world-first approval in UK
Human Gene Editing
Nov 16, 2023
M&A
Graphite Bio merges with LENZ Therapeutics to advance treatment of eye condition
Human Gene Editing
Nov 15, 2023
FDA approval
Intellia Therapeutics receives Orphan Drug Designation for NTLA-2002
Human Gene Editing
Nov 14, 2023
Partnerships
Genevant Sciences and Novo Nordisk partners to develop treatment for hemophilia A
Human Gene Editing
Nov 6, 2023
Partnerships
Cellectis signs investment agreement with AstraZeneca worth up to USD 245 million to develop next-gen therapeutics
Human Gene Editing
Nov 1, 2023
Partnerships
‧
M&A
Verve expands collaboration with Eli Lilly following Lilly’s acquisition of Verve’s product rights from Beam Therapeutics
Human Gene Editing
Oct 31, 2023
FDA approval
Vertex-CRISPR sickle cell gene editing treatment exa-cel nears FDA approval
Human Gene Editing
Oct 31, 2023
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.